The corporate, which makes most of its income from the U.S., Europe and the UK, at the moment employs about 3,400 individuals throughout India, the U.S. and the UK.
The transfer comes as India’s drug analysis, growth and manufacturing sector is increasing quickly as international pharma firms shift excessive‑worth jobs to India as a consequence of cheaper manufacturing and a powerful expertise pool and as they search to unfold out their provide chains.
The Indian contract drug analysis and manufacturing sector is forecast to greater than double to $57.94 billion between 2025 and 2031, in response to market analysis agency Mordor Intelligence.
Sai Life’s new hires might be in scientific, technical and administration roles within the southern Indian metropolis of Hyderabad, the place the agency operates its largest R&D centre to help drug growth, knowledge‑enabled drug discovery and industrial manufacturing scale‑up.
There’s a “international supply-chain rebalancing” underway, the agency’s CEO and Managing Director Krishna Kanumuri mentioned in an announcement.
Sai Life has invested greater than $219 million to increase manufacturing over the past six years.
